Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group-Reference-Cited by-同舟云学术

Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group

Published:2008-07-02 Issue:11 Volume:23 Page:1033-1039
ISSN:0179-1958
Container-title:International Journal of Colorectal Disease
language:en
Short-container-title:Int J Colorectal Dis

Author:

Müller C. I.,Schulmann K.,Reinacher-Schick A.,Andre N.,Arnold D.,Tannapfel A.,Arkenau H.,Hahn S. A.,Schmoll S. H.-J.,Porschen R.,Schmiegel W.,Graeven U.

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00384-008-0504-2.pdf

Reference42 articles.

1. Ferlay J, Bray F, Pisani P et al (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5, version 2.0. IARC, Lyon, France

2. Kelly HGoldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23:4553–4560

3. Meyerhardt JAMayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476–487

4. Jiricny JNyström-Lahti M (2000) Mismatch repair defects in cancer. Curr Opin Genet Dev 10:157–161

5. Grady WM (2004) Genomic instability and colon cancer. Cancer Metastasis Rev 23:11–27

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitochondrial DNA Copy Number as a Biomarker for Guiding Adjuvant Chemotherapy in Stages II and III Colorectal Cancer Patients with Mismatch Repair Deficiency: Seeking Benefits and Avoiding Harms;Annals of Surgical Oncology;2024-07-10

2. Tumorigenicity and prediction of clinical prognosis of patient‐derived gastric cancer organoids;Clinical and Translational Medicine;2024-02

3. Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer;Journal of Gastrointestinal Cancer;2023-08-23

4. DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and Prognosis;Pathobiology;2022-06-10

5. Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC;Future Oncology;2022-06